; and (ii) that are relevant to the performance of such pharmacy based on the type of pharmacy, drugs dispensed, and pharmacy services used to dispense and manage drugs. (C) Standardized pharmacy performance measures (i) In general Notwithstanding any other provision of law, the Secretary shall, taking into account evaluations under subparagraph (A), establish or adopt from one or more multi-stakeholder, neutral, consensus-based measure development organizations representing all types of pharmacies (including pharmacies not otherwise owned, controlled, or affiliated with any other pharmacy, plan, or pharmacy benefit manager) standardized pharmacy quality measures and performance criteria, such as cut points, or any type of payment to be used by a PDP sponsor offering a prescription drug plan and an MA organization offering an MA–PD plan for the purposes of determining incentive payments and price concessions or fees described in subparagraph (B). Such measures shall be evidence-based, feasible, appropriate, and achievable based on industry data, and focus on pharmacy performance and quality of care, as determined by the Secretary, that the pharmacy can impact based on covered part D drugs the pharmacy dispenses and manages. (ii) Maintenance of list The Secretary shall maintain a single list of measures established or adopted under this subparagraph. Such measures shall be evaluated and such list updated on an ongoing basis through stakeholder consensus organizations representing all types of pharmacies as referenced in clause (i) to ensure the measures on such list are evidence-based, feasible, appropriate, and achievable. Such list shall be published on a public website not later than January 1, 2024, and updated thereafter as appropriate as determined by the Secretary. (D) Transparency to pharmacy For plan years beginning on or after January 1, 2025, the Secretary shall establish a uniform process under which a PDP sponsor offering a prescription drug plan and an MA organization offering an MA–PD plan shall